The global Non-Small Cell Lung Cancer Market is estimated to be valued at Us$ 27252.31 Mn in 2023 and is expected to exhibit a CAGR Of 9.4% over the forecast period 2023 To 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all diagnosed lung cancer cases. NSCLC includes three main histotypes: squamous cell carcinoma, large cell carcinoma, and adenocarcinoma. Advances in targeted therapies and immunotherapies have improved treatment outcomes for patients.
Market key trends:
One of the major trends in the non-small cell lung cancer market is the increasing usage of targeted therapies and immunotherapies. Immunotherapies such as immune checkpoint inhibitors work by activating the body's immune system to fight cancer cells. Drugs such as nivolumab, pembrolizumab and atezolizumab have shown promising results in clinical trials. Targeted therapies work by blocking the growth and spread of cancer by interfering with specific molecules involved in tumor growth and progression. Some of the targeted therapies used in NSCLC include gefitinib, erlotinib, afatinib and osimertinib which target mutations in EGFR gene. The increasing focus on precision medicines is expected to drive the non-small cell lung cancer market during the forecast period.
Segment Analysis
The global non-small cell lung cancer market is segmented type, treatment, end-user and region. Based on type, the non-small cell lung cancer market is segmented into squamous cell carcinoma, large cell carcinoma and adenocarcinoma. Among these, adenocarcinoma is the dominant as well as the fastest growing segment owing to its increasing prevalence globally. Adenocarcinoma usually starts in mucus-producing cells and is the most common type of non-small cell lung cancer.
Key Takeaways
The Global Non-Small Cell Lung Cancer Market Size is expected to witness high growth, exhibiting a CAGR of 9.4% over the forecast period, due to increasing prevalence of smoking and rising air pollution.
Regional analysis:
North America dominates the global non-small cell lung cancer market and is expected to continue its dominance over the forecast period. This is attributed to the presence of established healthcare facilities and high awareness among the population regarding lung cancer. Asia Pacific is poised to be the fastest growing region owing to increasing healthcare expenditure and rising cigarette consumption in developing countries of this region.
Key players:
Key players operating in the non-small cell lung cancer market are Pfizer Inc., AstraZeneca plc, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Boehringer Ingelheim GMBH, Novartis AG, Bristol-Myers Squibb Company, and Merck & Co., Inc. These players are focusing on developing advanced therapeutics to strengthen their market position. For instance, in 2022, Merck & Co. received FDA approval for Keytruda, an immuno-oncology drug for the treatment of non-small cell lung cancer.
Non-Small Cell Lung Cancer market OverviewNon-Small Cell Lung Cancer Market Report offers an industry-wide analysis of the market, including precise assessment of the demand for the Non-Small Cell Lung Cancer Market and accurate market insights that allow readers to identify the existing opportunities and threats and optimize their investments.
It offers the global sector across key regional markets and gives an extensive investigation and statistical analysis of vital market elements.
The study also performs an elaborate industry-wide competitive analysis, highlighting the major companies in the Non-Small Cell Lung Cancer Market that regulate a substantial portion of the global market share and infers beneficial prospects and hurdles to help the reader invest wisely.It also includes an extensive investigation on Non-Small Cell Lung Cancer manufacturers, the expansion strategies adopted by the companies to capitalize on the existing growth prospects, the financial standing, and the individual market share of the leading participants, providing the readers a comprehensive overview of the competitive scenario.To get a PDF Sample Copy (including TOC, Table of content, and facts and figures) of the Non-Small Cell Lung Cancer market report, visit@ https://www.reportsanddata.com/sample-enquiry-form/1475The following manufacturers have been studied in this report by assessing the sales, gross revenue, and market share for each company:Tarceva, Avastin, Gemzar, Alimta, Taxotere, AstraZeneca, Roche, Merck KGa, Nlyte, and Panduit Corp. among others.The information relating to the Non-Small Cell Lung Cancer market that has been collected and analyzed in the report will allow a brand engaged in the sector to get the upper hand against leading players in the global landscape.
This report offers insights into the competitive scenario in the market.
It also delivers a progressive perspective relating to different market aspects driving or curtailing the growth of the market.Histology Outlook (Revenue, USD Billion; 2016-2026)Squamous Cell CarcinomaLarge Cell CarcinomaAdenocarcinomaTreatment Outlook (Revenue, USD Billion; 2016-2026)SurgeryRadiationChemotherapyTargeted Therapy DrugsDrug Class Outlook (Revenue, USD Billion; 2016-2026)Angiogenesis InhibitorEpidermal Growth Factor Receptor BlockerKinase InhibitorMicrotubule StabilizerFolate AntimetabolitesPD-1/ PD-L1 InhibitorTo inquire about report customization & check for availability of incredible discount rates on this report, visit@ https://www.reportsanddata.com/discount-enquiry-form/1475The report will offer a clear view of each and every fact relating to the industry, rendering it unnecessary to refer to any other source of information or a data source.
Our report will deliver all details relating to the historical development, existing scenario, and accurate insights into the Non-Small Cell Lung Cancer Market.Regional Landscape Analysis for Non-Small Cell Lung Cancer Market:North America (United States, Canada, and Mexico)Europe (Germany, France, UK, Russia, and Italy)Asia-Pacific (China, Japan, Korea, India, and Southeast Asia)South America (Brazil, Argentina, Colombia, etc.
The Global Non-Small Cell Lung Cancer Market size is forecast to reach USD 11.87 Billion by 2028, registering a CAGR of 6.2% over the forecast period, according to a new report by Reports and Data.
Non small cell lung cancer accounts for 80 percent to 85 percent of all lung cancer cases across the world, and this high proportion has prompted the majority of market leaders to focus on constant innovation of new therapies and improving the efficacy of existing medicines.
The expansion of the non small cell lung cancer market is further aided by an increase in the frequency of diagnosis of non small cell lung cancer and increased awareness about the disease in developed and emerging countries.
This, combined with increased spending by leading companies in research and development operations, as well as the inclusion of non-small cell cancer therapies in major market participants' pipelines, is fueling global market expansion.One of the challenges of the non-small cell lung cancer market is the high cost of treatment.
Surgery performed at an early stage is the best chance to cure non small cell lung cancer.· Among the various drug class segments of the market, angiogenesis inhibitor accounted for the largest market share in 2020.
Development of public healthcare centers and subsidized treatment will fuel the market growth.Top Companies Profiled in the Report Include:Tarceva, Avastin, Gemzar, Alimta, Taxotere, AstraZeneca, Roche, Merck KGa, Nlyte, and Panduit Corp. among others.Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/1475Market Overview:The pharma and healthcare industry has undergone a revolutionary change owing to the COVID-19 pandemic with individuals increasing their focus on health and wellness.
